tirzepatide peak sales vs semaglutide: A new battle in obesity treatment Eli Lilly Overtakes Novo Nordisk
Description
there is no one-size-fits-all shortcut
More recently, there has been a growing concern among health care professionals due to easy accessibility of Tirzepatide by the public without medical advice and increased cases of unsupervised and off-label use for cosmetic weight loss 3
While both medications are administered through once-weekly subcutaneous injections, they have distinct dosing regimens and pen delivery systems
Theres no requirement to increase on exactly a four-week schedule
Patients on both medications often hit the SURMOUNT-1 average (20.9% body weight loss) faster than expected
